The Technical Analyst
Transmedics Group Inc [TMDX]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Transmedics Group Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.90% $88.88
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 907.74 mill |
| EPS: | -0.770 |
| P/E: | -115.43 |
| Earnings Date: | Apr 28, 2024 |
| SharesOutstanding: | 32.72 mill |
| Avg Daily Volume: | 0.740 mill |
| RATING 2024-04-24 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -115.43 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.52x |
| Company: PE -115.43 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 84.22 - 93.54 ( +/- 5.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-17 | Hassanein Waleed H | Sell | 4 000 | Stock Option (Right to Buy) |
| 2024-04-17 | Hassanein Waleed H | Buy | 4 000 | Common Stock |
| 2024-04-17 | Hassanein Waleed H | Sell | 4 000 | Common Stock |
| 2024-04-10 | Hassanein Waleed H | Sell | 12 000 | Stock Option (Right to Buy) |
| 2024-04-10 | Hassanein Waleed H | Buy | 12 000 | Common Stock |
| INSIDER POWER |
|---|
| 2.74 |
| Last 100 transactions |
| Buy: 325 751 | Sell: 307 375 |
Forecast:
16:00 - $88.99
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $88.99
Forecast 2: 16:00 - $88.99
Forecast 3: 16:00 - $88.99
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $88.88 (-1.90% ) |
| Volume | 0.538 mill |
| Avg. Vol. | 0.740 mill |
| % of Avg. Vol | 72.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TMDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $88.73 | N/A | Active |
|---|
TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-16 16:05:00 - Press Release
Transmedics To Report First Quarter 2024 Financial Results On April 30, 2024
Andover, mass. , april 16, 2024 /prnewswire/ -- transmedics group, inc. ("transmedics") (nasdaq: tmdx), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on tuesday, april 30, 2024.
2024-04-08 16:05:00 - Press Release
Transmedics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Andover, mass. , april 8, 2024 /prnewswire/ -- transmedics group, inc. ("transmedics") (nasdaq: tmdx), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on april 4, 2024, transmedics granted non-qualified stock options to purchase an aggregate of 9,722 shares of its common stock and an aggregate of 6,322 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with transmedics.
2024-03-19 16:05:00 - Press Release
Transmedics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Andover, mass. , march 19, 2024 /prnewswire/ -- transmedics group, inc. ("transmedics") (nasdaq: tmdx), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on march 15, 2024, transmedics granted non-qualified stock options to purchase an aggregate of 9,418 shares of its common stock and an aggregate of 6,149 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with transmedics.
2024-03-02 19:30:00 - Press Release
Tmdx Investor Notice: Rosen, A Global And Leading Law Firm, Encourages Transmedics Group, Inc. Investors To Inquire About Securities Class Action Investigation - Tmdx
New york , march 2, 2024 /prnewswire/ -- why: rosen law firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of transmedics group, inc. (nasdaq: tmdx) resulting from allegations that transmedics may have issued materially misleading business information to the investing public. so what: if you purchased transmedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
2024-02-28 16:06:00 - Press Release
Transmedics To Present At Upcoming March Investor Conferences
Andover, mass. , feb. 28, 2024 /prnewswire/ -- transmedics group, inc. ("transmedics") (nasdaq: tmdx), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
Latest News
2024-04-24 19:05:32 - Zacks Investment Research
TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.
2024-04-23 11:07:14 - Zacks Investment Research
TransMedics (TMDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-04-22 19:21:21 - Zacks Investment Research
TransMedics (TMDX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.
2024-04-15 19:21:05 - Zacks Investment Research
TransMedics (TMDX) Flat As Market Sinks: What You Should Know
TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.
2024-04-12 16:30:00 - InvestorPlace
Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024
Whether you believe them or not, analyst ratings have long been a strong indicator of the stock price's direction. There is a direct correlation between how Wall Street analysts rate a stock and how it performs.
2024-04-12 06:30:00 - InvestorPlace
3 Must-Own Stocks for Sustained Growth Over the Next 18 Months
The bull market continues, and the S&P 500 is hardly giving up any gains. Indeed, the momentum from the October 2023 lows has been incredible.
2024-03-19 01:46:56 - Seeking Alpha
TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
FY2023: TransMedics' revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone. TransMedics' Organ Care System (OCS) could drive transplant volumes by expanding the donor pool through increased utilization of marginal (including DCD) organs. As the only FDA-approved multi-organ platform, TransMedics faces relatively limited competition at the moment and looks well positioned to establish a market leading position.
2024-03-14 10:51:06 - Zacks Investment Research
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
2024-03-12 14:14:40 - Seeking Alpha
TransMedics Group: Huge Opportunity In Organ Transplants
TransMedics Group is transforming the organ transplant landscape with its expansive transplant solutions. The company has a proven technology, FDA approved, making it a rare early commercial-stage investment opportunity. TransMedics has led to double-digit growth in liver, lung, and heart transplants in the U.S., with a market size of over $1.5 billion in 2023.
2024-03-03 06:23:00 - The Motley Fool
2 No-Brainer Growth Stocks to Buy With $100 in March
The stock market keeps reaching new heights, but you can still find terrific growth stocks trading for reasonable prices. PubMatic's supply-side advertising platform generates a strong profit, and it has room to grow.